Journals / Çocuk Dergisi / 2010 / Cilt: 10 - Sayı: 1

A Case Report with Neonatal Supraventricular Tachycardia: Review of Current Treatment

Yenidoğanda Supraventriküler Taşikardi Vakası: Güncel Tedavi Yaklaşımı

Pages
51–54
Publication Date
2010-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report a neonate with supraventricular tachycardia who presented with heart failure and treated with amiodaron is presen- ted

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Supraventricular tachycardia is the most common cardiac arrhythmia in neonatal period and childhood.
📊
Key Findings & Data:While the incidence of supraventricular tachycardia was reported to be 1:25,000 at 1967, with more sensitive diagnostic met- hods the incidence during neonatal period and in all ages of childhood is now estimated to be 1:100 and 1:200-250 respectively.
💡
Conclusion & Impact:In this case report a neonate with supraventricular tachycardia who presented with heart failure and treated with amiodaron is presen- ted
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Supraventriküler taşikardi · yenidoğan · tedavi

Abstract

Supraventricular tachycardia is the most common cardiac arrhythmia in neonatal period and childhood. While the incidence of supraventricular tachycardia was reported to be 1:25,000 at 1967, with more sensitive diagnostic met- hods the incidence during neonatal period and in all ages of childhood is now estimated to be 1:100 and 1:200-250 respectively. Clinical findings are more severe in neonates with supraventricular tachycardia than in older children. Supraventricular tachycardia may present with heart failu- re and hydrops fetalis. Symptoms of supraventricular tach- ycardia requires immediate treatment and supraventricular tachycardia may be a cause of morbidity and mortality during neonatal period due to recurrent attacks of arrhy- thmia refractory to drug treatment. In this case report a neonate with supraventricular tachycardia who presented with heart failure and treated with amiodaron is presen- ted

Özet

Supraventriküler taşikardi çocukluk çağının ve yenidoğan döneminde en sık karşılaşılan kardiak aritmidir. Sıklığı 1967’lerde 1:25,000 olarak bildirilirken, tanı yöntemlerin- de iyileşme ile günümüzde bütün çocukluk yaşlarında 1:100, yenidoğan döneminde 1:200-250 sıklıkta tanımlan- maktadır. Yenidoğanlarda klinik bulgular çocukluk çağın- daki supraventriküler taşikardiye göre daha ağır seyret- mektedir. Kalp yetersizliği ve hidrops fetalis şeklinde klinik bulgularla karşımıza çıkabilir. Acil tedavisi gerekli olup; bazen ilaçlara dirençli ve yineleyebilen ataklar nedeniyle yenidoğan döneminde morbidite ve mortaliteye neden ola- bilir. Bu makalede yenidoğan döneminde kalp yetersizliği ile başvuran ve amiadaron tedavisi ile taşikardisi kontrol altına alınan supraventriküler taşikardili bir vaka sunul- muştur

🔖

Cite This Article

BOLAT, F., USLU, S., CÖMERT, S., DİNDAR, A., BÜLBÜL, A., NUHOĞLU, A. (2010). A Case Report with Neonatal Supraventricular Tachycardia: Review of Current Treatment. Çocuk Dergisi, Cilt: 10 - Sayı: 1, 51–54. https://ajindex.com/articles/246978

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Moak JP. Supraventricular tachycardia in the neonate and infant. Prog Pediatr Cardiol 2000; 11:25-38
  2. Lewis L, Poojari G, Sanoj KM, Kamath SP, Kachane YP. Neonatal arrhythmia with diaphragmatic eventration. Indian J Pediatr 2008; 75:1083-5
  3. De Giovanni JV, Dindar A, Griffith MJ, et al. Recovery pattern of left ventricular dysfunction following radiofrequency ablation of incessant supraventricular tachycardia in infants and children. Heart 1998; 79:588-92 4. International Liaison Committee on Resuscitation (ILCOR). International Guidelines 2005 for CPR and ECG-a consensus on science. Circulation 2005; 112; III-73-III-90
  4. American Heart Association (AHA) Guidelines for CPR and ECG. Circulation 2005; 112; IV-67-IV-77
  5. Park MK. Cardiac arrhytmias. In: Park MK. Pediatric Cardiology for Practitioners. 5th ed. Philedelphia, USA: Mosby Elsevier Pres, 2008: 417-444
  6. Kantoch MJ. Supraventricular tachycardia in children Indian J Pediatr 2005; 72:609-19
  7. Gilljam T, Jaeggi E, Gow RM. Neonatal supraventricular tachycardia: outcomes over a 27-year period at a single institution. Acta Paediatr 2008; 97:1035-9
  8. Dixon J, Foster K, Wyllie J, Wren C. Guidelines and adenosine dosing in supraventricular tachycardia. Arch Dis Child 2005; 90(11):1190-1
  9. Balaguer Gargallo M, Jordán García I, Caritg Bosch J, Cambra Lasaosa FJ, Prada Hermogenes F, Palomaque Rico A. Supraventricular tachycardia in infants and children. An Pediatr 2007; 67:133-8
  10. Etheridge SP, Judd VE. Supraventricular tachycardia in infancy: evaluation, management, and follow-up. Arch Pediatr Adolesc Med 1999; 153:267-71
  11. Yildirim SV, Tiker F, Cengiz N, Kiliçdağ H. Recurrent Supraventricular Tachycardia in a Newborn Treated with Amiodarone: Is Hyperkalemia the Apparent Cause?. Pediatr Cardiol 2005; 26:879-80
  12. Etheridge SP, Janet C, Steven J. Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants. American Heart Journal 2001; 141:105-10
  13. O’Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants?. J Am Coll Cardiol 1995; 26:991-4.